SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ERGO (fights fat, diabetes II, and Heart disease)
An SI Board Since July 1997
Posts SubjectMarks Bans Symbol
110 3 0 ERGO
Emcee:  jim detwiler Type:  Unmoderated
Ergo Science Corporation (ERGO) has shown that the administration of brain-altering drugs can shift daily hormone secretion patterns which may provide effective therapy for Type II diabetes and obesity. In humans, adult-onset or Type II diabetes is characterized by low-sensitivity of the body's tissues to insulin for moving blood sugar (glucose) into various organs including the brain, heart, and skeletal muscle. Diabetes has become one of the largest medical problems in many industrialized countries. Of an estimated 16 million diagnosed and undiagnosed diabetics, approximately 15 million people suffered from Type II diabetes last year in the U.S. alone and that number is expected to increase to 32 million by 2010. Obesity afflicts approximately 58 million Americans, or approximately 33% of the U.S. adult population, and over 45% of the entire population is overweight. Obesity is considered a primary risk factor for Type II diabetes, cardiovascular diseases, and many other "diseases of civilization" including some cancers. Moreover, approximately 30% of obese Americans have been diagnosed with Type II diabetes. On June 23 rd , ERGO hel d a press conference to di scuss data that was presented at the annual Ameri can Di abetes Associ ati on meetings. Based on the clinical utility demonstrated in Phase III trials for ERGOSET and the competitive advantage that we expect the product to build over currently marketed Type II diabetes therapies once, and if, the drug is approved, we believe the Company's products will serve an important role in the treatment of diabetes, and possibly obesity. ERGO has demonstrated in Phase III clinical trials that ERGOSET is safe, e fficaceous, and has clinical utility in the control of glucose metabolism for the treatment of Type II diabetes. The Company has completed three Phase III trials involving over 620 patients with Type II diabetes at 17 investigational sites, and announced preliminary analysis of these trials in July and December of 1996. In ERGOSET efficacy trials, the Company has observed that the drug not only improves control over glucose, a minimal requirement for approval, but it has certain advantages in the management of fat metabolism. If ERGO is able to commercialize a Type II diabetes therapy that not only improves control over glucose, but also decreases circulating cholesterol and other fats, the Company could have a significant competitive advantage over other currently marketed diabetes treatments that do not directly impact lipid (fat) metabolism and risk factors for cardiovascular disease.
ú, ERGO's approach to treating diabetes and obesity represents a new class of therapeutics. In contrast, most of the other therapeutic classes of drugs only treat the "symptoms" of the disease: Precose slows the absorption of carbohydrates, thus decreasing the spike of high blood sugar seen after eating; Glucophage stimulates the secretion of insulin, thus increasing circulating insulin; Rezulin stimulates the production of glucose transporting proteins by fat cells and skeletal muscle cells. However, circadian rhythm function has been demonstrated in numerous animal species to be the root cause of changes in metabolic, some of which are excellent models for human Type II diabetes and obesity. ERGOSET is the first antidiabetic postulated to have a direct effect on circadian rhythms and the scientists at ERGO are pioneers in the fields of chronobiology and neuroendochrinology. ERGO's approach to Type II diabetes treatment is different from the relatively limited actions on select "downstream" biochemical/physiological events that contribute to diabetes by current therapies.
_
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
110 Zoro, I have reviewed some of your posts. Are you planning to add more in biotDavid Ritz-1/2/2000
109 Good luck. I took a year end tax loss and got out. I will not be getting backZoro-12/31/1999
108 Just bought some ERGO for about 1/2 the cash in the company per share. I figurJim H-12/31/1999
107 News out last nite; see biz.yahoo.com good news/bad news; lots of volume today,Zoro-10/22/1999
106 Interesting; it dragged along down 1/16 for most of the day, and then hit the Zoro-8/27/1999
105 Any clue why the stock is up .25 today? (20% gain)Gary Stern-8/27/1999
104 I doubt that the appeal being denied is the reason for the fall. When the appeGary Stern-6/10/1999
103 Thread: Any idea why we're getting killed today? Appeal denied maybe?Zoro-6/9/1999
102 And it probably has a big NOL, and, the public shell has value in and of itselfGary Stern-5/6/1999
101 Is anyone out there??? This company still has $31+ million in cash hangin arounZoro-5/6/1999
100 Lots of positive action today. Zoro-5/3/1999
99 Very, very quiet here. Is the company just burning cash, all be it at a scaledZoro-4/19/1999
98 At long last, some positive action in this stock. Perhaps the appeal will be mZoro-3/23/1999
97 Great buy? Better news? Based on what? I'm sorry, I don't see it. tommysdad-11/24/1998
96 Let's see what happens with the appeal. This may be a great time to purcfordor-11/23/1998
95 what is the time frame for down the road... Codee-11/23/1998
94 ERGO is a great buy after the news today. It has lost half of its value. IMOfordor-11/23/1998
93 This sounds very encouraging: messages.yahoo.com@m2.yahoo.com Regards, TOPSTtopstock-11/16/1998
92 I think there is going to be FDA news on the 22nd...could be a good time to takmfr-11/6/1998
91 Hi Guys, seems like the thread is pretty quite. Yahoo thread is pretty active topstock-11/4/1998
90 << It went below 4 today......get ready to wallpaper the bathroom.>>Mike M-6/9/1998
89 I got a bridge I'll sell ya. ;-) Pullin-GS-6/8/1998
88 mfr, Today's BioCentury mentions that ERGO met with the FDA and is puttingRudy Saucillo-6/8/1998
87 I thought ERGO was going to meet with the FDA, but haven't heard anything..mfr-6/5/1998
86 It went below 4 today......get ready to wallpaper the bathroom.Sigismund Pikul-6/2/1998
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):